17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study - PubMed (original) (raw)
Clinical Trial
. 2003 Mar-Apr;11(2):239-44.
Affiliations
- PMID: 12611754
Clinical Trial
17beta-estradiol reduces plasma Abeta40 for HRT-naïve postmenopausal women with Alzheimer disease: a preliminary study
Laura D Baker et al. Am J Geriatr Psychiatry. 2003 Mar-Apr.
Abstract
Objective: One mechanism to support the potentially beneficial effects of estrogen in the brain for postmenopausal women potentially involves the hormone's ability to favorably alter the processing of amyloid-precursor protein (APP), believed to play an important role in the pathobiology of Alzheimer disease (AD). The authors evaluated the effects of estrogen administration on plasma concentration of one by-product of APP processing, Abeta40, for postmenopausal women with AD.
Methods: In a placebo-controlled, double blind, parallel-group design study, 20 women were randomized to receive either 0.10 mg/day of transdermal 17beta-estradiol or a placebo for 8 weeks and were retrospectively evaluated as to whether basal levels of Abeta40 were affected by pre-study use of hormone replacement therapy (HRT). Blood samples were collected and cognitive tests were administered at baseline; at Weeks 3, 5, and 8 during treatment; and again 8 weeks after treatment termination.
Results: For the group as a whole, plasma Abeta40 was not reliably reduced in response to short-term estradiol administration. For HRT-naïve subjects, baseline Abeta40 concentrations were higher than those of previous HRT users, and controlled estradiol administration significantly reduced plasma Abeta40 by the end of the 8-week treatment period.
Conclusions: These results provide preliminary clinical evidence to support an effect of estradiol on Abeta-processing for AD women who are HRT-naïve. This finding suggests that the hormone may serve as an Abeta-lowering agent for HRT-naïve AD women, which may, in turn, have ultimate ramifications for the progression of AD pathology.
Similar articles
- Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.
Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR. Asthana S, et al. Psychoneuroendocrinology. 1999 Aug;24(6):657-77. doi: 10.1016/s0306-4530(99)00020-7. Psychoneuroendocrinology. 1999. PMID: 10399774 Clinical Trial. - Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition.
Kantarci K, Lowe VJ, Lesnick TG, Tosakulwong N, Bailey KR, Fields JA, Shuster LT, Zuk SM, Senjem ML, Mielke MM, Gleason C, Jack CR, Rocca WA, Miller VM. Kantarci K, et al. J Alzheimers Dis. 2016 May 7;53(2):547-56. doi: 10.3233/JAD-160258. J Alzheimers Dis. 2016. PMID: 27163830 Free PMC article. Clinical Trial. - Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain.
Petanceska SS, Nagy V, Frail D, Gandy S. Petanceska SS, et al. Neurology. 2000 Jun 27;54(12):2212-7. doi: 10.1212/wnl.54.12.2212. Neurology. 2000. PMID: 10881241 - Hormone replacement therapy in postmenopausal women.
Yasui T, Uemura H, Takikawa M, Irahara M. Yasui T, et al. J Med Invest. 2003 Aug;50(3-4):136-45. J Med Invest. 2003. PMID: 13678382 Review. - Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women.
Rao CV. Rao CV. Reprod Sci. 2017 Mar;24(3):355-368. doi: 10.1177/1933719116658705. Epub 2016 Jul 20. Reprod Sci. 2017. PMID: 27436369 Review.
Cited by
- Use of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease: A Systematic Review.
Cardinali CAEF, Martins YA, Torrão AS. Cardinali CAEF, et al. Drugs Aging. 2021 Sep;38(9):769-791. doi: 10.1007/s40266-021-00878-y. Epub 2021 Aug 3. Drugs Aging. 2021. PMID: 34342862 - Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.
Lönneborg A. Lönneborg A. Mol Diagn Ther. 2008;12(5):307-20. doi: 10.1007/BF03256296. Mol Diagn Ther. 2008. PMID: 18803429 Review. - Engineering poly(lactic-co-glycolic acid) (PLGA) micro- and nano-carriers for Controlled Delivery of 17β-Estradiol.
Prakapenka AV, Bimonte-Nelson HA, Sirianni RW. Prakapenka AV, et al. Ann Biomed Eng. 2017 Jul;45(7):1697-1709. doi: 10.1007/s10439-017-1859-8. Epub 2017 Jun 20. Ann Biomed Eng. 2017. PMID: 28634732 Free PMC article. Review. - Androgens, aging, and Alzheimer's disease.
Pike CJ, Rosario ER, Nguyen TV. Pike CJ, et al. Endocrine. 2006 Apr;29(2):233-41. doi: 10.1385/ENDO:29:2:233. Endocrine. 2006. PMID: 16785599 Review. - Transdermal treatment options for neurological disorders: impact on the elderly.
Priano L, Gasco MR, Mauro A. Priano L, et al. Drugs Aging. 2006;23(5):357-75. doi: 10.2165/00002512-200623050-00001. Drugs Aging. 2006. PMID: 16823990 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical